Shots:
- Immutep and Dr. Reddy’s Laboratories have entered into a strategic collaboration and exclusive licensing agreement to develop and commercialize Eftilagimod Alfa (efti) across all countries outside North America, Europe, Japan, and Greater China
- As per the deal, Immutep will receive a $20M (~AUD 30.2M) upfront payment from Dr. Reddy’s, plus potential milestone payments of up to $349.5M (~AUD 528.4M) and double-digit royalties on commercial sales in the licensed markets.
- Efti is a soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells, under evaluation in a P-III trial for advanced or metastatic NSCLC and is also being studied in head & neck, breast, and soft tissue sarcomas
Ref: Immutep | Image: Immutep and Dr. Reddy’s Laboratories | Press Release
PharmaShots, your go-to media platform for customized news across multiple therapeutic areas. For more information, reach us at connect@pharmashots.com
